Literature DB >> 21189420

Molecular characterization of the NPC1L1 variants identified from cholesterol low absorbers.

Li-Juan Wang1, Jing Wang, Na Li, Liang Ge, Bo-Liang Li, Bao-Liang Song.   

Abstract

Niemann-Pick C1-like 1 (NPC1L1) is an essential protein for dietary cholesterol absorption. Nonsynonymous (NS) variants of NPC1L1 in humans have been suggested to associate with cholesterol absorption variations. However, information concerning the characteristics and mechanism of these variants in cholesterol uptake is limited. In this study, we analyzed the cholesterol uptake ability of the 19 reported NS variants of NPC1L1 identified from cholesterol low absorbers. Among these variants, L110F, R306C, A395V, G402S, T413M, R693C, R1214H, and R1268H could partially mediate cellular cholesterol uptake and were categorized as partially dysfunctional variants. The other 11 variants including T61M, N132S, D398G, R417W, G434R, T499M, S620C, I647N, G672R, S881L, and R1108W could barely facilitate cholesterol uptake, and were classified into the severely dysfunctional group. The partially dysfunctional variants showed mild defects in one or multiple aspects of cholesterol-regulated recycling, subcellular localization, glycosylation, and protein stability. The severely dysfunctional ones displayed remarkable defects in all these aspects and were rapidly degraded through the ER-associated degradation (ERAD) pathway. In vivo analyses using adenovirus-mediated expression in mouse liver confirmed that the S881L variant failed to localize to liver canalicular membrane, and the mice showed defects in biliary cholesterol re-absorption, while the G402S variant appeared to be similar to wild-type NPC1L1 in mouse liver. This study suggests that the dysfunction of the 19 variants on cholesterol absorption is due to the impairment of recycling, subcellular localization, glycosylation, or stability of NPC1L1.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21189420      PMCID: PMC3044996          DOI: 10.1074/jbc.M110.178368

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  41 in total

1.  Ufd1 is a cofactor of gp78 and plays a key role in cholesterol metabolism by regulating the stability of HMG-CoA reductase.

Authors:  Jian Cao; Jiang Wang; Wei Qi; Hong-Hua Miao; Jing Wang; Liang Ge; Russell A DeBose-Boyd; Jing-Jie Tang; Bo-Liang Li; Bao-Liang Song
Journal:  Cell Metab       Date:  2007-08       Impact factor: 27.287

2.  Extracellular loop C of NPC1L1 is important for binding to ezetimibe.

Authors:  Adam B Weinglass; Martin Kohler; Uwe Schulte; Jessica Liu; Emmanuel O Nketiah; Anu Thomas; William Schmalhofer; Brande Williams; Wolfgang Bildl; Daniel R McMasters; Kevin Dai; Lindsey Beers; Margaret E McCann; Gregory J Kaczorowski; Maria L Garcia
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-05       Impact factor: 11.205

3.  Sequence variation in NPC1L1 and association with improved LDL-cholesterol lowering in response to ezetimibe treatment.

Authors:  Jason S Simon; Maha C Karnoub; David J Devlin; Maria G Arreaza; Ping Qiu; Stephanie A Monks; Michael E Severino; Paul Deutsch; Joanne Palmisano; Alan B Sachs; Marvin L Bayne; Andrew S Plump; Eric E Schadt
Journal:  Genomics       Date:  2005-11-16       Impact factor: 5.736

4.  Effect of ezetimibe coadministered with statins in genotype-confirmed heterozygous FH patients.

Authors:  Livia Pisciotta; Tommaso Fasano; Antonella Bellocchio; Letizia Bocchi; Raffaella Sallo; Raffaele Fresa; Isabella Colangeli; Alfredo Cantafora; Sebastiano Calandra; Stefano Bertolini
Journal:  Atherosclerosis       Date:  2006-11-30       Impact factor: 5.162

5.  Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels.

Authors:  Jonathan C Cohen; Alexander Pertsemlidis; Saleemah Fahmi; Sophie Esmail; Gloria L Vega; Scott M Grundy; Helen H Hobbs
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-31       Impact factor: 11.205

6.  Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe.

Authors:  Ryan E Temel; Weiqing Tang; Yinyan Ma; Lawrence L Rudel; Mark C Willingham; Yiannis A Ioannou; Joanna P Davies; Lisa-Mari Nilsson; Liqing Yu
Journal:  J Clin Invest       Date:  2007-07       Impact factor: 14.808

7.  Genetic variation in ABC G5/G8 and NPC1L1 impact cholesterol response to plant sterols in hypercholesterolemic men.

Authors:  Hai L Zhao; Adrielle H Houweling; Catherine A Vanstone; Stephanie Jew; Elke A Trautwein; Guus S M J E Duchateau; Peter J H Jones
Journal:  Lipids       Date:  2008-10-11       Impact factor: 1.880

8.  The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1.

Authors:  Liang Ge; Jing Wang; Wei Qi; Hong-Hua Miao; Jian Cao; Yu-Xiu Qu; Bo-Liang Li; Bao-Liang Song
Journal:  Cell Metab       Date:  2008-06       Impact factor: 27.287

Review 9.  Zetia: inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia.

Authors:  Harry R Davis; Enrico P Veltri
Journal:  J Atheroscler Thromb       Date:  2007-06       Impact factor: 4.928

10.  Functional characterization of genetic variants in NPC1L1 supports the sequencing extremes strategy to identify complex trait genes.

Authors:  Saleemah Fahmi; Chendong Yang; Sophie Esmail; Helen H Hobbs; Jonathan C Cohen
Journal:  Hum Mol Genet       Date:  2008-04-15       Impact factor: 6.150

View more
  26 in total

Review 1.  The delicate balance between secreted protein folding and endoplasmic reticulum-associated degradation in human physiology.

Authors:  Christopher J Guerriero; Jeffrey L Brodsky
Journal:  Physiol Rev       Date:  2012-04       Impact factor: 37.312

Review 2.  Dyslipidaemia of diabetes and the intestine.

Authors:  Gerald H Tomkin; Daphne Owens
Journal:  World J Diabetes       Date:  2015-07-10

3.  Novel gene-by-environment interactions: APOB and NPC1L1 variants affect the relationship between dietary and total plasma cholesterol.

Authors:  Daniel S Kim; Amber A Burt; Jane E Ranchalis; Ella R Jarvik; Elisabeth A Rosenthal; Thomas S Hatsukami; Clement E Furlong; Gail P Jarvik
Journal:  J Lipid Res       Date:  2013-03-11       Impact factor: 5.922

4.  Ezetimibe blocks the internalization of NPC1L1 and cholesterol in mouse small intestine.

Authors:  Chang Xie 谢畅; Zhang-Sen Zhou 周章森; Na Li 李钠; Yan Bian 卞艳; Yong-Jian Wang 王永建; Li-Juan Wang 王丽娟; Bo-Liang Li 李伯良; Bao-Liang Song 宋保亮
Journal:  J Lipid Res       Date:  2012-07-17       Impact factor: 5.922

Review 5.  Role of the gut in lipid homeostasis.

Authors:  Nada A Abumrad; Nicholas O Davidson
Journal:  Physiol Rev       Date:  2012-07       Impact factor: 37.312

6.  The clathrin adaptor Numb regulates intestinal cholesterol absorption through dynamic interaction with NPC1L1.

Authors:  Pei-Shan Li; Zhen-Yan Fu; Ying-Yu Zhang; Jin-Hui Zhang; Chen-Qi Xu; Yi-Tong Ma; Bo-Liang Li; Bao-Liang Song
Journal:  Nat Med       Date:  2013-12-15       Impact factor: 53.440

Review 7.  An update on the pathogenesis of cholesterol gallstone disease.

Authors:  Agostino Di Ciaula; David Q-H Wang; Piero Portincasa
Journal:  Curr Opin Gastroenterol       Date:  2018-03       Impact factor: 3.287

8.  The N-terminal domain of NPC1L1 protein binds cholesterol and plays essential roles in cholesterol uptake.

Authors:  Jin-Hui Zhang; Liang Ge; Wei Qi; Liqing Zhang; Hong-Hua Miao; Bo-Liang Li; Maojun Yang; Bao-Liang Song
Journal:  J Biol Chem       Date:  2011-05-20       Impact factor: 5.157

9.  The clathrin adaptor proteins ARH, Dab2, and numb play distinct roles in Niemann-Pick C1-Like 1 versus low density lipoprotein receptor-mediated cholesterol uptake.

Authors:  Jian Wei; Zhen-Yan Fu; Pei-Shan Li; Hong-Hua Miao; Bo-Liang Li; Yi-Tong Ma; Bao-Liang Song
Journal:  J Biol Chem       Date:  2014-10-20       Impact factor: 5.157

Review 10.  Molecular mechanisms of disease-causing missense mutations.

Authors:  Shannon Stefl; Hafumi Nishi; Marharyta Petukh; Anna R Panchenko; Emil Alexov
Journal:  J Mol Biol       Date:  2013-07-16       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.